Understanding Nebulizer Utilization by Patients and Healthcare Providers: A COPD Foundation Nebulizer Consortium Survey Study
Authors:
- Sergio MartinezSMSergio Martinez
- Jill OharJOJill Ohar
- Rajiv DhandRDRajiv Dhand
- M DrummondMDM Drummond
- Arzu AriArzu Ari
- Lewis Radonovich JrLJLewis Radonovich Jr
- Donald TashkinDTDonald Tashkin
Open Access
- 1 January 2026
- journal article
- research article
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 21, 1-12
Abstract
Rationale: Inhaled medications are the mainstay of chronic obstructive pulmonary disease (COPD) management. While consensus guidelines for pharmacological management in COPD are well-established, few guidelines exist regarding inhaled medication delivery systems. The COPD Foundation Nebulizer Consortium conducted a cross-sectional survey of patients with COPD and healthcare providers to understand their perceptions and utilization of nebulized medications. Methods: An online survey was conducted from February 7 through April 9, 2024. Patients completed a 42-question survey, including demographic information, tobacco use, symptoms severity, and the role of nebulizers in their treatment. Healthcare providers responded to a 17-question survey about their clinical experience with nebulized medications. Results: We analyzed responses from 347 patients and 39 healthcare providers. Among patients, 76.4% (265/347) were ≥ 65 years old, 72.0% (250/347) were female, 93.4% (324/347) were white, 90.5% (314/347) had a current or former smoking history, 77.6% (263/339) reported at least one exacerbation in the past year, and 70.8% (240/339) used some form of supplemental oxygen. Nebulizer use was reported by 84.1% (292/347) of patients. Among nebulizer users, 94.5% (276/292) used short-acting while only 22.3% (65/292) used long-acting nebulized medications. Patients reported that hand-held inhaler devices were easier to use (69.8%, 171/245), but nebulized therapy led to better symptom control (64.9%, 159/245) and had lower copays (67.8%, 166/245). Among prescribers surveyed, most (82.1%, 32/39) believed nebulizers were preferable for patients experiencing exacerbations. Impediments to wider use of nebulizers included difficulties with insurance coverage (69.2%, 27/39), cost (53.8%, 21/39), and lack of combination nebulized drugs (46.2%, 18/39). Two-thirds of providers thought that nebulizers were underused. Conclusion: We demonstrate that while patients and providers both perceive nebulizers as preferred in clinical management of COPD, there is discordance between patient and provider perception of nebulizer use on the basis of cost and feasibility of use.Keywords
This publication has 28 references indexed in Scilit:
- Greenhouse Gas Emissions and Costs of Inhaler Devices in the USJAMA, 2024
- Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPDChest, 2024
- GOLD COPD report: 2024 updateThe Lancet Respiratory Medicine, 2023
- Guidance on Mitigating the Risk of Transmitting Respiratory Infections During Nebulization by the COPD Foundation Nebulizer ConsortiumChest, 2023
- Recent advances predict a bright future for nebulizersCurrent Opinion in Pulmonary Medicine, 2023
- Estimating the national carbon footprint of inhalers in healthcareIrish Journal of Medical Science (1971 -), 2022
- Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary diseaseRespiratory Medicine, 2019
- Efficacy and safety of glycopyrrolate/eFlow® CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trialsRespiratory Medicine, 2017
- Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPDCochrane Database of Systematic Reviews, 2016
- A long-term prospective assessment of home nebulizer treatmentRespiratory Medicine, 1992